大麻二酚油用于缓解晚期癌症症状的IIb期随机、安慰剂对照、剂量递增、双盲研究(MedCan1-CBD)
本研究纳入144例接受姑息治疗的晚期癌症伴症状困扰患者,随机接受滴定大麻二酚(CBD)油或安慰剂28天。第14天CBD组与安慰剂组ESAS总症状困扰评分变化无显著差异(P=.24),应答比例亦无显著差异(P=.13)。结论:CBD油未在专科姑息治疗基础上额外改善症状困扰。
要点
- 第14天ESAS总症状困扰评分变化CBD组-3.0 vs 安慰剂组-6.2,组间无显著差异(P=.24)。
- 应答比例(TSDS下降≥6)CBD组44.8% vs 安慰剂组58.7%,无显著差异(P=.13)。
- 除呼吸困难在CBD组更常见外,不良事件组间无显著差异。
核心结论
- CBD油未能在专科姑息治疗基础上额外改善晚期癌症患者的症状困扰。
研究设计与样本
- IIb期随机、安慰剂对照、剂量递增、双盲研究,纳入144例接受姑息治疗的晚期癌症伴症状困扰(ESAS总分≥10/90)成人患者。
- CBD油100 mg/mL,从每日一次0.5 mL滴定至每日三次每次2 mL,或匹配安慰剂,持续28天;主要终点为第14天ESAS总症状困扰评分(TSDS)。
主要发现
- 第14天TSDS自基线变化:安慰剂组-6.2(标准差14.5)vs CBD组-3.0(标准差15.2),组间无显著差异(P=.24)。
- 应答比例(第14天TSDS下降≥6):安慰剂组37/63(58.7%)vs CBD组26/58(44.8%),无显著差异(P=.13)。
- ESAS各组分随时间改善(下降),组间无差异;患者自选CBD中位剂量为每日400 mg,与阿片剂量无相关性。
- CBD对生活质量、抑郁或焦虑未检测到效果;除呼吸困难在CBD组更常见外,不良事件组间无显著差异。
- 第14天报告感觉好转或明显好转者:CBD组53% vs 安慰剂组65%;第28天:CBD组70% vs 安慰剂组64%。
关键数值与推荐
- 主要终点为第14天ESAS总症状困扰评分(TSDS)。
- 应答定义为第14天TSDS下降≥6。
- 入组要求ESAS总分≥10/90。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS: Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14. Response was defined as a decrease in TSDS by ≥ 6 at day 14. Secondary outcomes were ESAS TSDS over time, individual symptom scores, patient-determined effective dose, opioid use, Global Impression of Change, depression, anxiety, quality of life, and adverse events. RESULTS: Of the 144 patients randomly assigned, the planned sample size of 58 participants on CBD and 63 on placebo reached the primary analysis point (day 14). The unadjusted change in TSDS from baseline to day 14 was -6.2 (standard deviation, 14.5) for placebo and -3.0 (standard deviation, 15.2) for CBD with no significant difference between arms (P = .24). Similarly, there was no detected difference in proportion of responders (placebo: 37 of 63 [58.7%], CBD: 26 of 58 [44.8%], P = .13). All components of ESAS improved (fell) over time with no difference between arms. The median dose of participant-selected CBD was 400 mg per day with no correlation with opioid dose. There was no detectable effect of CBD on quality of life, depression, or anxiety. Adverse events did not differ significantly between arms apart from dyspnea that was more common with CBD. Most participants reported feeling better or much better at days 14 (53% CBD and 65% placebo) and 28 (70% CBD and 64% placebo). CONCLUSION: CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.
引用
- Hardy J, Greer R, Huggett G, et al. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol. 2022. PMID: 36409969. doi:10.1200/JCO.22.01632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。